Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Amara SarwalDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.
Robert E BoucherDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-5455-002
Sydney E HartsellDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-7328-3732
Guo WeiDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4971-8430
Jincheng ShenDepartment of Population Health Sciences and Division of Epidemiology, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.
Glenn M ChertowDepartments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0002-7599-0534
Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.ORCID 0000-0002-2225-383
Alfred K CheungDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.
John William McEvoyDivision of Cardiology, University of Galway, Galway, Ireland.ORCID 0000-0001-6530-5479
Tom GreeneDepartment of Population Health Sciences and Division of Epidemiology, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.
Srinivasan BeddhuDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-3312-315
Funding
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
TRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6M
Objectively Measured Sedentary Behavior and Physical Activity in PREVENTABLE StudyR01AG074592 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2021 to 2025
$3.4M
Sit Less, Interact and Move More (SLIMM) 2 StudyR01DK128640 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2021 to 2025
$3.3M
Long-term metabolic effects of kidney events with intensive SBP controlR01DK118219 · NIDDK · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN, CHERTOW, GLENN MATTHEW · 2018 to 2021
$1.2M
Influence of baseline DBP on the effects of BP lowering on clinical outcomes: A participant level meta-analysis of RCTsR21HL145494 · NHLBI · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2019 to 2020
$229k
National Center for Advancing Translational Sciences of the National Institutes of Health UM1TR004409NCATS NIH HHS UM1 TR004409NHLBI Division of Intramural Research R21HL145494NHLBI NIH HHS R21 HL145494NHLBI NIH HHS T32 HL007576NIA NIH HHS R01 AG074592NIDDK NIH HHS R01 DK118219NIDDK NIH HHS R01DK118219NIDDK NIH HHS R01 DK128640
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
AASK (African American Study of Kidney Disease and Hypertension)BPcardiovascular eventsclinical hypertensionclinical nephrologyclinical trialhypertension and cardiorenal disorderskidney diseasemortalityoutcomes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Baseline Diastolic BP and BP-Lowering Effects on Cardiovascular Outcomes and All-Cause Mortality: A Meta-Analysis. · full record | OpenQuestion